- Home
- ETY vs ACAD Comparison
ETY vs ACAD Comparison
Compare ETY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETY
- ACAD
- Stock Information
- Founded
- ETY 2006
- ACAD 1993
- Country
- ETY United States
- ACAD United States
- Employees
- ETY N/A
- ACAD N/A
- Industry
- ETY Finance Companies
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- ETY Finance
- ACAD Health Care
- Exchange
- ETY Nasdaq
- ACAD Nasdaq
- Market Cap
- ETY 2.1B
- ACAD 2.5B
- IPO Year
- ETY N/A
- ACAD 2004
- Fundamental
- Price
- ETY $14.32
- ACAD $16.93
- Analyst Decision
- ETY
- ACAD Buy
- Analyst Count
- ETY 0
- ACAD 15
- Target Price
- ETY N/A
- ACAD $24.21
- AVG Volume (30 Days)
- ETY 247.3K
- ACAD 1.7M
- Earning Date
- ETY 01-01-0001
- ACAD 05-07-2025
- Dividend Yield
- ETY 7.21%
- ACAD N/A
- EPS Growth
- ETY N/A
- ACAD N/A
- EPS
- ETY N/A
- ACAD 1.37
- Revenue
- ETY N/A
- ACAD $996,283,000.00
- Revenue This Year
- ETY N/A
- ACAD $13.07
- Revenue Next Year
- ETY N/A
- ACAD $10.06
- P/E Ratio
- ETY N/A
- ACAD $12.55
- Revenue Growth
- ETY N/A
- ACAD 22.42
- 52 Week Low
- ETY $10.59
- ACAD $13.40
- 52 Week High
- ETY $13.46
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- ETY 59.86
- ACAD 64.73
- Support Level
- ETY $13.99
- ACAD $14.45
- Resistance Level
- ETY $14.37
- ACAD $15.31
- Average True Range (ATR)
- ETY 0.24
- ACAD 0.66
- MACD
- ETY 0.13
- ACAD 0.27
- Stochastic Oscillator
- ETY 96.50
- ACAD 90.91
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.